Skip to main content

Table 3 Serum glucose and lipid profile levels distribution among different combinations of HAART taken by study participants at Burayu Health Center, Addis Ababa, Ethiopia, 2012

From: Antiretroviral treatment associated hyperglycemia and dyslipidemia among HIV infected patients at Burayu Health Center, Addis Ababa, Ethiopia: a cross-sectional comparative study

Glucose/lipid profile NVP versus EFV based combination of ARVs P-value
NVP (n=65) EFV (n=61)
N (%) N (%)
Glucose ≤110 60(92.3) 56(91.8) 0.917
>110 5(7.7) 5(8.2)
Triglyceride <150 37(56.9) 30(49.2) 0.384
≥150 28(43.1) 31(50.8)
Total cholesterol <200 37(56.9) 36(59) 0.812
≥200 28(43.1) 25(41)
HDL-cholesterol <40 28(43.1) 36(59) 0.074
≥40 37(56.9) 25(41)
LDL-cholesterol <130 48(73.8) 49(80.3) 0.388
≥130 17(26.2) 12(19.7)
Glucose/lipid profile D4T versus AZT based combination of ARVs P-value
D4T (n=47) AZT (n=67)
N (%) N (%)
Glucose ≤110 40(85.1) 64(95.5) 0.053
>110 7(14.9) 3(4.5)
Triglyceride <130 25(53.2) 35(52.2) 0.920
≥130 22(46.8) 32(47.8)
Total cholesterol <200 28(59.6) 39(58.2) 0.884
≥200 19(40.4) 28(41.8)
HDL-cholesterol <40 26(55.3) 33(49.3) 0.524
≥40 21(44.7) 34(50.7)
LDL-cholesterol <130 37(78.7) 53(79.1) 0.961
≥130 10(21.3) 14(20.9)
  1. AZT, Zidovudine; d4T, stavudine; EFV, efavirenz; NVP, nevirapine; p, significance level.